Identification and Validation of MSX1 as a Key Candidate for Progestin Resistance in Endometrial Cancer.
Linlin YangYunxia CuiTing HuangXiao SunYudong WangPublished in: OncoTargets and therapy (2020)
Our study identified that the gene of MSX1 promised to be the specific indicator and therapeutic target for progestin resistance. This would shed new light on the underlying biological mechanism to overcome progestin resistance of endometrial cancer.